Literature DB >> 23294549

Self-administration of subcutaneous depot medroxyprogesterone acetate by adolescent women.

Rebekah L Williams1, Devon J Hensel, J Dennis Fortenberry.   

Abstract

BACKGROUND: Intramuscular depot medroxyprogesterone acetate (DMPA-IM) is now available in subcutaneous (SC) formulation, potentially allowing for home-based self-administration. We examined adolescents' interest in and proficiency at DMPA-SC self-administration. STUDY
DESIGN: This is a planned secondary analysis of a randomized controlled trial comparing pain between DMPA-IM and DMPA-SC. In the trial, study participants (N=55) aged 14-21 years were recruited at DMPA initiation and randomized to receive DMPA-IM or DMPA-SC. Participants received the alternate formulation at 3 months, chose formulation at 6 months and could learn self-administration at 9 months. The current analysis is of the women who chose self-administration of DMPA-SC. Proficiency was rated for each step of self-administration: independently [I], with reassurance [R], with verbal instruction [V] or nurse performed [RN]. Data were analyzed using descriptive and comparative statistics.
RESULTS: Thirty-five percent (19/55) of participants learned self-administration. Proficiency ratings were as follows: chose injection site (I=78.9%, R=5.3%, V=5.3%, RN=10.5%), cleaned site (I=89.5%, RN=10.5%), assembled injection device (I=47.4%, R=36.8%, V=15.8%), self-injected (I=31.6%, R=36.8%, V=15.8%, RN=15.8%) and disposed of device (I=21.1%, R=21.1%, RN=57.9%).
CONCLUSIONS: Many adolescents are interested in and capable of DMPA-SC self-administration with brief education and minimal assistance.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adolescent; Contraception; Depot medroxyprogesterone acetate; Self-injection

Mesh:

Substances:

Year:  2013        PMID: 23294549      PMCID: PMC3745808          DOI: 10.1016/j.contraception.2012.11.019

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.

Authors:  John Jain; Caryn Dutton; Antonia Nicosia; Charlie Wajszczuk; Frederick R Bode; Daniel R Mishell
Journal:  Contraception       Date:  2004-07       Impact factor: 3.375

2.  Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002.

Authors:  Joyce C Abma; Gladys M Martinez; William D Mosher; Brittany S Dawson
Journal:  Vital Health Stat 23       Date:  2004-12

3.  Self-injection of monthly combined hormonal contraceptive.

Authors:  Nancy L Stanwood; Kara Eastwood; Alison Carletta
Journal:  Contraception       Date:  2005-11-14       Impact factor: 3.375

4.  The acceptability of self-administration of subcutaneous Depo-Provera.

Authors:  Fatim Lakha; Charlotte Henderson; Anna Glasier
Journal:  Contraception       Date:  2005-07       Impact factor: 3.375

5.  Pharmacist-administered subcutaneous depot medroxyprogesterone acetate: a pilot randomized controlled trial.

Authors:  Carla Picardo; Stefanie Ferreri
Journal:  Contraception       Date:  2010-02-19       Impact factor: 3.375

6.  Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2006-2010 national survey of family growth.

Authors:  Gladys Martinez; Casey E Copen; Joyce C Abma
Journal:  Vital Health Stat 23       Date:  2011-10

7.  "I want to do it myself!" Interferon self-injection for children with chronic viral hepatitis.

Authors:  Mary Jane Ott
Journal:  Gastroenterol Nurs       Date:  2005 Sep-Oct       Impact factor: 0.978

8.  Internet-based screening for Chlamydia trachomatis to reach non-clinic populations with mailed self-administered vaginal swabs.

Authors:  Charlotte A Gaydos; Karen Dwyer; Mathilda Barnes; Patricia A Rizzo-Price; Billie Jo Wood; Toni Flemming; M Terry Hogan
Journal:  Sex Transm Dis       Date:  2006-07       Impact factor: 2.830

9.  Contraceptive efficacy and safety of DMPA-SC.

Authors:  J Jain; A J Jakimiuk; F R Bode; D Ross; A M Kaunitz
Journal:  Contraception       Date:  2004-10       Impact factor: 3.375

10.  Can e-technology through the Internet be used as a new tool to address the Chlamydia trachomatis epidemic by home sampling and vaginal swabs?

Authors:  Charlotte A Gaydos; Mathilda Barnes; Bulbul Aumakhan; Nicole Quinn; Patricia Agreda; Pamela Whittle; Terry Hogan
Journal:  Sex Transm Dis       Date:  2009-09       Impact factor: 2.830

  10 in total
  5 in total

1.  Randomized clinical trial of self versus clinical administration of subcutaneous depot medroxyprogesterone acetate.

Authors:  Anitra Beasley; Katharine O'Connell White; Serge Cremers; Carolyn Westhoff
Journal:  Contraception       Date:  2014-02-07       Impact factor: 3.375

2.  Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?

Authors:  Chelsea B Polis; Sharon L Achilles; Zdenek Hel; Janet P Hapgood
Journal:  Contraception       Date:  2017-12-11       Impact factor: 3.375

Review 3.  Hormonal and intrauterine methods for contraception for women aged 25 years and younger.

Authors:  Jamie Krashin; Jennifer H Tang; Sheila Mody; Laureen M Lopez
Journal:  Cochrane Database Syst Rev       Date:  2015-08-17

Review 4.  Contraception and endometriosis: challenges, efficacy, and therapeutic importance.

Authors:  Edith Weisberg; Ian S Fraser
Journal:  Open Access J Contracept       Date:  2015-07-27

5.  Ugandan providers' views on the acceptability of contraceptive self-injection for adolescents: a qualitative study.

Authors:  Jane Cover; Allen Namagembe; Justine Tumusiime; Jeanette Lim; Carie Muntifering Cox
Journal:  Reprod Health       Date:  2018-10-03       Impact factor: 3.223

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.